Dr. Mark H. O'Hara, MD

Dr. O'Hara practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. O'Hara's NPI, 1225291933, was assigned on July 3, 2008. Dr. O'Hara holds Pennsylvania license MD444150.

Dr. O'Hara's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. O'Hara's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. O'Hara is also affiliated with Penn Presbyterian Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. O'Hara to 2 more hospitals and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Hara practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. O'Hara's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. O'Hara is licensed in Pennsylvania.

CMS data shows 594 Medicare services from Dr. O'Hara across 5 procedure codes in 2024, for 160 Medicare patients. Medicare paid $40,698 for them.

CMS counts 160 Medicare patients who saw Dr. O'Hara in 2024. The largest group is 65 to 74, with 96 patients. 73% of them have high cholesterol, and 69% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Hara's median patient age at 70, with 44% women.

In 2024, Dr. O'Hara wrote 167 Medicare Part D claims for 69 patients. 80% of them were for generic drugs. CMS names the drug for 45 of them, across 3 drugs with 11 or more claims each, at $18,037 in total drug cost. In 2023, CMS named 49 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. O'Hara for performance year 2024, reported as part of a group. Dr. O'Hara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Hara as offering telehealth.

Dmand AI links Dr. O'Hara to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. O'Hara that name 3 trials.

CMS Open Payments shows 21 general payments to Dr. O'Hara from 5 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 52% of the total. Exelixis Inc. paid the most, $2,776. It also lists 5 research payments totaling $1,425 from 2016 to 2018, naming 3 clinical trials.